Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Free Cash Flow (2016 - 2025)

Aptevo Therapeutics (APVO) has disclosed Free Cash Flow for 11 consecutive years, with -$5.2 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 9.59% to -$5.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$212000.0 through Dec 2025, up 99.11% year-over-year, with the annual reading at -$25.6 million for FY2025, 7.56% down from the prior year.
  • Free Cash Flow hit -$5.2 million in Q4 2025 for Aptevo Therapeutics, down from $18.7 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $18.7 million in Q3 2025 to a low of -$7.7 million in Q1 2021.
  • Historically, Free Cash Flow has averaged -$4.0 million across 5 years, with a median of -$5.3 million in 2021.
  • Biggest five-year swings in Free Cash Flow: tumbled 245.66% in 2024 and later skyrocketed 459.89% in 2025.
  • Year by year, Free Cash Flow stood at -$4.0 million in 2021, then plummeted by 48.55% to -$5.9 million in 2022, then increased by 12.06% to -$5.2 million in 2023, then fell by 11.05% to -$5.8 million in 2024, then grew by 9.59% to -$5.2 million in 2025.
  • Business Quant data shows Free Cash Flow for APVO at -$5.2 million in Q4 2025, $18.7 million in Q3 2025, and -$7.1 million in Q2 2025.